Clinical Trials Directory

Trials / Completed

CompletedNCT04136548

Analgesics in the Pre-hospital Setting: Implications on Hemorrhage Tolerance - Fentanyl

Status
Completed
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
41 (actual)
Sponsor
University of Texas Southwestern Medical Center · Academic / Other
Sex
All
Age
18 Years – 45 Years
Healthy volunteers
Accepted

Summary

The purpose of this project is to test how fentanyl, an analgesic currently employed in the pre-hospital setting by the US Army, alters the capacity to tolerate a hemorrhagic insult in humans.

Detailed description

Pain management on the battlefield is critical for the wellbeing of the soldier. Given that a hemorrhagic injury on the battlefield is virtually always associated with pain, it is paramount that the selected pain medication does not disrupt appropriate physiological mechanisms that are beneficial towards the maintenance of blood pressure and vital organ blood flow during that hemorrhagic insult. Current guidelines for the selection of pain medications of a hemorrhaging soldier are based upon limited scientific evidence, with the vast majority of supporting studies being conducted on anesthetized animals. Thus, the interaction between hemorrhagic shock and pain medications commonly employed on the battlefield is yet to be determined in the conscious humans. With this background, we will test the hypothesis that fentanyl will impair the capacity for a conscious human to tolerate a hemorrhagic insult. The obtained data will provide the necessary scientific evidence in humans to support the Committee on Tactical Combat Casualty Care (CoTCCC) guidelines on the analgesic of choice for moderate to severe injuries where the casualty is in hemorrhagic shock. Notably, such data will identify the analgesic that least compromises a human's ability to tolerate a hemorrhagic insult, ultimately providing critical information to the combat medic on which analgesic should be employed for such an injury.

Conditions

Interventions

TypeNameDescription
DRUGFentanylSubjects will receive 75 ug Fentanyl while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.
OTHERPlaceboSubjects will receive saline while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.

Timeline

Start date
2019-06-01
Primary completion
2020-11-18
Completion
2020-11-18
First posted
2019-10-23
Last updated
2022-01-24
Results posted
2022-01-24

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT04136548. Inclusion in this directory is not an endorsement.